We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.88 | -0.68% | 127.92 | 129.76 | 127.985 | 129.76 | 7,446,078 | 01:00:00 |
From May 2019 to May 2024
By Michael Dabaie
Gossamer Bio Inc. (GOSS) said it is in a clinical collaboration agreement with Merck & Co. Inc. (MRK) to evaluate the combination of Gossamer's investigational candidate GB1275 and Merck's Keytruda in patients with advanced solid tumors.
Gossamer will conduct a Phase 1/2 study, Keynote-A36, in advanced solid tumors, with the Phase 1 consisting of dose escalation of three GB1275 regimens including one with Keytruda. The Phase 2 consists of expansion cohorts evaluating GB1275 in combination with Keytruda or chemotherapy.
The KEYNOTE-A36 Phase 1/2 trial is underway, enrolling patients in the U.S. and U.K. to treat solid tumor types, including pancreatic, gastric, esophageal, colorectal, prostate and triple negative breast.
Gossamer said it expects to report initial data from the Phase 1 portion of the study in the second half of 2020.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 12, 2019 07:41 ET (12:41 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
